Profusa, Inc. (PFSA)
$1.28-1.54%Close
SELLCRISIS · day 37
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $6M
- Beta
- 0.50
- P/E (TTM)
- -0.01
- Short % float
- 3.53%
- Days to cover
- 1.0
- SI change
- +409.3%
- 1W
- -22.89%
- 1M
- -50.58%
- vs SPY 1W
- -22.75%
- vs SPY 1M
- -53.09%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 15
- VALUE
- 12
- GROWTH
- 35
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC88.9%
REV YoY-
ROE148.2%
EPS YoY-
ROA-
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.01
P/E FWD-
SECTOR PE20.34
INDUSTRY PE22.66
P/B-0.00
P/FCF-
EV/EBITDA-0.42
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.03
ND/EBITDA-
BETA0.50
Company news
FAQ
- What is LOPJLB’s current signal on PFSA?
- LOPJLB’s latest quantitative signal on Profusa, Inc. Common Stock (PFSA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PFSA in?
- Profusa, Inc. Common Stock (PFSA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Profusa, Inc. Common Stock (PFSA) do?
- Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Pla…